Jonathan E. Rosenberg

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.2K citations · Full text

Tumor Biology, Cancer Immunosurveillance, Tumour Response +12

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.2K citations · Full text

Cancer Immunosurveillance, Tumor Heterogeneity, Medicine +9

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations · Full text

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +8

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text

Urology, Genitourinary Cancer, Medicine +7

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

Jarushka Naidoo, Xuan Wang, Kaitlin M. Woo et al. · Journal of Clinical Oncology · 2016 · 1.1K citations · Full text